Free tool
Oncology stocks
We cover 20 companies grouped under the Oncology theme. The median market value in the group is $1.64B. Across the group, the median move over the past trading day is +0.10%. 100% of the 20 with a 200-day average trade above it. Price change over the past year runs from −20.3% to +264.9% across the middle 80 percent of the group, with a median of +72.1%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
20 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 132.16 EUR | +14.19% | +47.92% | +91.49% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $153.10 | +16.14% | +44.89% | +86.85% | Oct 29, 2026 |
| 0J9P.L | Incyte Corporation | $129.02 | +1.10% | +29.30% | +53.49% | Oct 27, 2026 |
| GE9.DE | Genmab A/S | 294.20 EUR | +17.26% | +9.78% | −11.12% | Nov 5, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $41.58 | +14.99% | +22.84% | +66.32% | Nov 9, 2026 |
| ZLAB | Zai Lab Limited | $26.03 | +39.80% | +50.20% | −20.06% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $28.44 | +42.41% | +90.62% | +254.61% | Nov 4, 2026 |
| ZYME | Zymeworks Inc. | $29.31 | +29.61% | +10.09% | +96.28% | Nov 5, 2026 |
| VIR | Vir Biotechnology, Inc. | $11.08 | +25.20% | +86.53% | +111.85% | Nov 4, 2026 |
| INBX | Inhibrx Biosciences, Inc. | $125.34 | +57.30% | +67.03% | +357.45% | Nov 13, 2026 |
| CGEM | Cullinan Therapeutics, Inc. | $22.85 | +30.80% | +125.79% | +188.15% | Nov 5, 2026 |
| JANX | Janux Therapeutics, Inc. | $18.89 | +25.93% | +38.39% | −19.10% | Nov 5, 2026 |
| SGMT | Sagimet Biosciences Inc. | $10.86 | +49.38% | +81.30% | +39.59% | Nov 12, 2026 |
| PRLD | Prelude Therapeutics Incorporated | $6.56 | +41.38% | +140.29% | +412.50% | Nov 11, 2026 |
| 0LOV.L | Verastem, Inc. | $7.15 | +3.62% | −1.79% | −19.93% | Nov 3, 2026 |
| 0XOD.L | UroGen Pharma Ltd. | $46.18 | −1.66% | +104.45% | +136.88% | Nov 5, 2026 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $11.30 | +24.38% | +43.58% | +7.93% | Nov 16, 2026 |
| HOWL | Werewolf Therapeutics, Inc. | $0.99 | +120.22% | +53.30% | −25.65% | Oct 30, 2026 |
| KYNB | Kyntra Bio, Inc. | $8.11 | +16.20% | −11.52% | −22.66% | Nov 9, 2026 |
| BFRI | Biofrontera Inc. | $1.53 | +37.84% | +111.03% | +77.91% | Nov 11, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.